These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 15868382)

  • 1. Multi-centre Phase II trial of the polyamine synthesis inhibitor SAM486A (CGP48664) in patients with metastatic melanoma.
    Millward MJ; Joshua A; Kefford R; Aamdal S; Thomson D; Hersey P; Toner G; Lynch K
    Invest New Drugs; 2005 Jun; 23(3):253-6. PubMed ID: 15868382
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase I and pharmacokinetic study of SAM486A, a novel polyamine biosynthesis inhibitor, administered on a daily-times-five every-three-week schedule in patients with Advanced solid malignancies.
    Siu LL; Rowinsky EK; Hammond LA; Weiss GR; Hidalgo M; Clark GM; Moczygemba J; Choi L; Linnartz R; Barbet NC; Sklenar IT; Capdeville R; Gan G; Porter CW; Von Hoff DD; Eckhardt SG
    Clin Cancer Res; 2002 Jul; 8(7):2157-66. PubMed ID: 12114416
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase I study of a new polyamine biosynthesis inhibitor, SAM486A, in cancer patients with solid tumours.
    Paridaens R; Uges DR; Barbet N; Choi L; Seeghers M; van der Graaf WT; Groen HJ; Dumez H; Buuren IV; Muskiet F; Capdeville R; Oosterom AT; de Vries EG
    Br J Cancer; 2000 Sep; 83(5):594-601. PubMed ID: 10944598
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical efficacy, tolerability, and safety of SAM486A, a novel polyamine biosynthesis inhibitor, in patients with relapsed or refractory non-Hodgkin's lymphoma: results from a phase II multicenter study.
    Pless M; Belhadj K; Menssen HD; Kern W; Coiffier B; Wolf J; Herrmann R; Thiel E; Bootle D; Sklenar I; Müller C; Choi L; Porter C; Capdeville R
    Clin Cancer Res; 2004 Feb; 10(4):1299-305. PubMed ID: 14977828
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I and pharmacological study of weekly administration of the polyamine synthesis inhibitor SAM 486A (CGP 48 664) in patients with solid tumors. European Organization for Research and Treatment of Cancer Early Clinical Studies Group.
    Eskens FA; Greim GA; van Zuylen C; Wolff I; Denis LJ; Planting AS; Muskiet FA; Wanders J; Barbet NC; Choi L; Capdeville R; Verweij J; Hanauske AR; Bruntsch U
    Clin Cancer Res; 2000 May; 6(5):1736-43. PubMed ID: 10815892
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biological activity of the S-adenosylmethionine decarboxylase inhibitor SAM486A in human breast cancer cells in vitro and in vivo.
    Hu X; Washington S; Verderame MF; Demers LM; Mauger D; Manni A
    Int J Oncol; 2004 Dec; 25(6):1831-8. PubMed ID: 15547724
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Population pharmacokinetics/toxicodynamics (PK/TD) relationship of SAM486A in phase I studies in patients with advanced cancers.
    Zhou H; Choi L; Lau H; Bruntsch U; Vries EE; Eckhardt G; Oosterom AT; Verweij J; Schran H; Barbet N; Linnartz R; Capdeville R
    J Clin Pharmacol; 2000 Mar; 40(3):275-83. PubMed ID: 10709156
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CGP 48664, a new S-adenosylmethionine decarboxylase inhibitor with broad spectrum antiproliferative and antitumor activity.
    Regenass U; Mett H; Stanek J; Mueller M; Kramer D; Porter CW
    Cancer Res; 1994 Jun; 54(12):3210-7. PubMed ID: 8205541
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of S-adenosylmethionine decarboxylase by inhibitor SAM486A connects polyamine metabolism with p53-Mdm2-Akt/protein kinase B regulation and apoptosis in neuroblastoma.
    Koomoa DL; Borsics T; Feith DJ; Coleman CC; Wallick CJ; Gamper I; Pegg AE; Bachmann AS
    Mol Cancer Ther; 2009 Jul; 8(7):2067-75. PubMed ID: 19584241
    [TBL] [Abstract][Full Text] [Related]  

  • 10. (18)F-labelled fluorodeoxyglucose-positron emission tomography (FDG-PET) heterogeneity of response is prognostic in dabrafenib treated BRAF mutant metastatic melanoma.
    Carlino MS; Saunders CA; Haydu LE; Menzies AM; Martin Curtis C; Lebowitz PF; Kefford RF; Long GV
    Eur J Cancer; 2013 Jan; 49(2):395-402. PubMed ID: 22981500
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictive value of early 18F-FDG PET/CT studies for treatment response evaluation to ipilimumab in metastatic melanoma: preliminary results of an ongoing study.
    Sachpekidis C; Larribere L; Pan L; Haberkorn U; Dimitrakopoulou-Strauss A; Hassel JC
    Eur J Nucl Med Mol Imaging; 2015 Mar; 42(3):386-96. PubMed ID: 25359635
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antitumor activity of N1,N11-bis(ethyl)norspermine against human melanoma xenografts and possible biochemical correlates of drug action.
    Porter CW; Bernacki RJ; Miller J; Bergeron RJ
    Cancer Res; 1993 Feb; 53(3):581-6. PubMed ID: 8425191
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of nude mice with 4-amidinoindan -1- one2 '- amidinohydrazone, a new S-adenosylmethionine decarboxylase inhibitor, delays growth and inhibits metastasis of human melanoma cells.
    Gutman M; Beltran PJ; Fan D; Delworth MG; Singh RK; Wilson MR; Fidler IJ
    Melanoma Res; 1995 Jun; 5(3):147-54. PubMed ID: 7640515
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II trial of flavopiridol, a cyclin dependent kinase inhibitor, in untreated metastatic malignant melanoma.
    Burdette-Radoux S; Tozer RG; Lohmann RC; Quirt I; Ernst DS; Walsh W; Wainman N; Colevas AD; Eisenhauer EA
    Invest New Drugs; 2004 Aug; 22(3):315-22. PubMed ID: 15122079
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inefficacy of F-18 fluorodeoxy-D-glucose-positron emission tomography scans for initial evaluation in early-stage cutaneous melanoma.
    Wagner JD; Schauwecker D; Davidson D; Logan T; Coleman JJ; Hutchins G; Love C; Wenck S; Daggy J
    Cancer; 2005 Aug; 104(3):570-9. PubMed ID: 15977211
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fluorodeoxyglucose positron emission tomography fails to detect distant metastases at initial staging of melanoma patients with metastatic involvement of sentinel lymph node.
    Wagner T; Meyer N; Zerdoud S; Julian A; Chevreau C; Payoux P; Courbon F
    Br J Dermatol; 2011 Jun; 164(6):1235-40. PubMed ID: 21332457
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metabolic response by FDG-PET to imatinib correlates with exon 11 KIT mutation and predicts outcome in patients with mucosal melanoma.
    Zukotynski K; Yap JT; Giobbie-Hurder A; Weber J; Gonzalez R; Gajewski TF; O'Day S; Kim K; Hodi FS; Van den Abbeele AD
    Cancer Imaging; 2014 Nov; 14(1):30. PubMed ID: 25609545
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Didemnin B in metastatic malignant melanoma: a phase II trial of the Southwest Oncology Group.
    Sondak VK; Kopecky KJ; Liu PY; Fletcher WS; Harvey WH; Laufman LR
    Anticancer Drugs; 1994 Apr; 5(2):147-50. PubMed ID: 8049497
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Observations with an S-adenosylmethionine decarboxylase inhibitor in rats with prostatic adenocarcinoma.
    Seiler N; Delcros JG; Cipolla B; Chamaillard L; Havouis R; Quemener V; Moulinoux JP
    Arzneimittelforschung; 1996 Mar; 46(3):311-5. PubMed ID: 8901156
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Key role for p27Kip1, retinoblastoma protein Rb, and MYCN in polyamine inhibitor-induced G1 cell cycle arrest in MYCN-amplified human neuroblastoma cells.
    Wallick CJ; Gamper I; Thorne M; Feith DJ; Takasaki KY; Wilson SM; Seki JA; Pegg AE; Byus CV; Bachmann AS
    Oncogene; 2005 Aug; 24(36):5606-18. PubMed ID: 16007177
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.